Anti-nicotine vaccine: current status
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20151380Keywords:
Anti-nicotine vaccine, Varenicline, Clinical trialAbstract
Tobacco abuse has an enormous impact on health. Nicotine is the main substance responsible for dependence on tobacco-containing products. The vast majority of cigarette smokers who try to quit ultimately fail because of high relapse rates. Clearly, novel approaches are needed for the treatment and prevention of nicotine addiction. Having an efficient vaccine that would generate antibodies to sequester the drug and prevent its access to the brain could go a long way toward helping a motivated addict quit an addiction.
References
World Health Organization. WHO Report on the Global Tobacco Epidemic, 2013: enforcing Bans on Tobacco Advertising, Promotion and Sponsorship. Geneva: World Health Organization; 2013.
Goniewicz ML, Delijewski M. Nicotine vaccines to treat tobacco dependence. Hum Vaccin Immunother. 2013;9(1):13-25.
O’ Brien CP. Drug addiction. In: Bruton L, Chabner B, Knollman B, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th Edition. New York: McGraw-Hill Companies Inc.; 2012: 649-68.
Raupach T, Hoogsteder PH, Onno van Schayck CP. Nicotine vaccines to assist with smoking cessation: current status of research. Drugs. 2012;72(4):e1-16.
Esterlis I, Hannestad JO, Perkins E, Bois F, D’Souza DC, Tyndale RF, et al. Effect of a nicotine vaccine on nicotine binding to ß2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. Am J Psychiatry. 2013;170(4):399-407.
Nabi Biopharmaceuticals: clinical Trials. NicVAX® (Nicotine Conjugate Vaccine. Available at http://www.nabi.com/pipeline/clinicaltrials.php. Accessed 11 November 2012.
Nabi Biopharmaceuticals: news Release. Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial. Available at http://www.phx.corporate-ir.net/phoenix.zhtml?c=100445&p=irolnewsArticle&ID=1626882&highlight. Accessed 14 January 2012.
Hoogsteder PH, Kotz D, van Spiegel PI, Viechtbauer W, Brauer R, Kessler PD, et al. The efficacy and safety of a nicotine conjugate vaccine (NicVAX(R)) or placebo co-administered with varenicline (Champix(R)) for smoking cessation: study protocol of a Phase IIb, double blind, randomized, placebo controlled trial. BMC Public Health. 2012;12:1052.
Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, Roubicek K, et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol. 2005;35(7):2031-40.
Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One. 2008;3(6):e2547.
Cytos Biotechnology. CYT002 Nic Qb: a Novel Vaccine for Nicotine Addiction. Zurich: Cytos Biotechnology; 2012. Available at http://www.cytos.com/userfiles/file/Cytos_ Press_E_091015.pdf. Accessed 15 January 2012.
Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev. 2012;8:CD007072.
Xenova Group plc: anti-Smoking Vaccine TA-NIC Preliminary 12 Month Clinical Trial Results [press release]. Berkshire, UK: Xenowa Group; 2005. Available at http://www.globenewswire.com/newsroom/news.html?d=73733. Accessed 15 January 2012.
ClinicalTrials.gov. Available at http://www.clinicaltrials.gov/ct2/show/NCT00633321?term=TA-NIC&rank=1. Accessed 14 January 2012.
Tonstad S, Heggen E, Giljam H, Lagerbäck PÅ, Tønnesen P, Wikingsson LD, et al. Niccine®, a nicotine vaccine, for relapse prevention: a Phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res. 2013;15(9):1492-501.
Selecta Biosciences: recent News. Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068, a First-in-Class Synthetic Nicotine Vaccine for Smoking Cessation and Relapse Prevention. Available at http://www.selectabio.com/news/recent-news/Selecta-Biosciences-Initiates-Phase-1-Clinical-Study-of-SEL-068.cfm. Accessed 14 January 2012.
